Mevastatin inhibits isoprenoid biosynthesis by inhibition of HMG-CoA reductase (Ki for acid form is 1 nM) and therefore blocks protein isoprenylation and reduces plasma cholesterol levels in humans. It causes cells to arrest early in the G1 phase. Mevastatin is a close structural analog of lovastatin and both agents have the same biochemical and pharmacological activities. Mevastatin is inactive in cell-free assays. In cells however, it is hydrolyzed to the active free acid form by intracellular esterases.
Product Details
| Alternative Name: | Compactin |
| |
| Formula: | C23H34O5 |
| |
| MW: | 390.5 |
| |
| CAS: | 73573-88-3 |
| |
| Purity: | ≥95% (HPLC) |
| |
| Identity: | Determined by 1H-NMR. |
| |
| Appearance: | White to off-white solid. |
| |
| Solubility: | Soluble in DMSO (20mg/ml) or 100% ethanol (25mg/ml). |
| |
| Shipping: | Ambient |
| |
| Long Term Storage: | -20°C |
| |
| Regulatory Status: | RUO - Research Use Only |
| |
Please mouse over
Product Literature References
The discovery and development of HMG-CoA reductase inhibitors: A. Endo; J. Lipid Res.
33, 1569 (1992),
Abstract;
The dual role of mevalonate in the cell cycle: V. Quesney-Huneeus, et al.; J. Biol. Chem.
258, 378 (1983),
Abstract;
Essential role for mevalonate synthesis in DNA replication: V. Quesney-Huneeus, et al.; PNAS
76, 5056 (1979),
Abstract;
